|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Multiple Sclerosis | |||||
| Urinary Tract Infections | |||||
| Bladder Dysfunction | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Communicable Diseases | |||||
| Infection | |||||
| Sclerosis | |||||
| 3 | More general conditions related to this trial | ||||
| Autoimmune Diseases | |||||
| Autoimmune Diseases of the Nervous System | |||||
| Demyelinating Autoimmune Diseases, CNS | |||||
| Demyelinating Diseases | |||||
| Immune System Diseases | |||||
| Nervous System Diseases | |||||
| Pathologic Processes | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Cranberry | |||||
| Placebo | |||||
| 5 | Sponsors listed in this trial | ||||
| Rennes University Hospital | |||||
| Pierre Fabre Laboratories | |||||
| Ministry of Health, France | |||||